SG11201608397UA - Glyt1 inhibitors for use in the treatment of hematological disorders - Google Patents
Glyt1 inhibitors for use in the treatment of hematological disordersInfo
- Publication number
- SG11201608397UA SG11201608397UA SG11201608397UA SG11201608397UA SG11201608397UA SG 11201608397U A SG11201608397U A SG 11201608397UA SG 11201608397U A SG11201608397U A SG 11201608397UA SG 11201608397U A SG11201608397U A SG 11201608397UA SG 11201608397U A SG11201608397U A SG 11201608397UA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- hematological disorders
- glyt1 inhibitors
- glyt1
- inhibitors
- Prior art date
Links
- 208000014951 hematologic disease Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14166497 | 2014-04-30 | ||
PCT/EP2015/059037 WO2015165842A1 (en) | 2014-04-30 | 2015-04-27 | Glyt1 inhibitors for use in the treatment of hematological disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201608397UA true SG11201608397UA (en) | 2016-11-29 |
Family
ID=50677958
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201608397UA SG11201608397UA (en) | 2014-04-30 | 2015-04-27 | Glyt1 inhibitors for use in the treatment of hematological disorders |
SG10201909382U SG10201909382UA (en) | 2014-04-30 | 2015-04-27 | Glyt1 inhibitors for use in the treatment of hematological disorders |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201909382U SG10201909382UA (en) | 2014-04-30 | 2015-04-27 | Glyt1 inhibitors for use in the treatment of hematological disorders |
Country Status (18)
Country | Link |
---|---|
US (1) | US9877963B2 (pt) |
EP (1) | EP3137073B1 (pt) |
JP (1) | JP6283766B2 (pt) |
KR (1) | KR101869185B1 (pt) |
CN (1) | CN106163520B (pt) |
AR (1) | AR100209A1 (pt) |
CY (1) | CY1120508T1 (pt) |
ES (1) | ES2683184T3 (pt) |
HR (1) | HRP20181205T1 (pt) |
MA (1) | MA39927B1 (pt) |
MY (1) | MY189930A (pt) |
PH (1) | PH12016501784A1 (pt) |
PT (1) | PT3137073T (pt) |
RS (1) | RS57535B1 (pt) |
SG (2) | SG11201608397UA (pt) |
SI (1) | SI3137073T1 (pt) |
TR (1) | TR201809598T4 (pt) |
WO (1) | WO2015165842A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3199156A1 (de) * | 2016-02-01 | 2017-08-02 | Heinrich-Heine-Universität Düsseldorf | Verwendung von glycin-transporter-1-antagonisten als zentralnervöse analgetika |
CU20200106A7 (es) * | 2018-06-20 | 2021-08-06 | Axcella Health Inc | Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias |
CN115279372A (zh) * | 2020-01-09 | 2022-11-01 | 迪斯克医药公司 | 用甘氨酸转运蛋白抑制剂治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法 |
WO2022192731A1 (en) * | 2021-03-12 | 2022-09-15 | Disc Medicine, Inc. | Compositions and methods for treating anemia associated with a ribosomal disorder |
JP2024518091A (ja) * | 2021-05-14 | 2024-04-24 | ディスク・メディシン・インコーポレイテッド | グリシン輸送阻害剤を用いて赤血球増殖性プロトポルフィリン症、x連鎖プロトポルフィリン症または先天性赤血球増殖性ポルフィリン症を処置する方法 |
JP2024520391A (ja) * | 2021-05-27 | 2024-05-24 | ディスク・メディシン・インコーポレイテッド | ビトペルチンの固体形態を用いて赤血球増殖性プロトポルフィリン症、x連鎖プロトポルフィリン症または先天性赤血球増殖性ポルフィリン症を処置する方法 |
WO2023235326A1 (en) * | 2022-05-31 | 2023-12-07 | Disc Medicine, Inc. | Compositions and methods for treating hepatic porphyrias with glycine transport inhibitors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ME00116B (me) * | 2003-08-11 | 2010-10-10 | Hoffmann La Roche | Piperazin sa ili supstituisanom fenil grupom i njihova upotreba kao inhibitora glyt1 |
RS51204B (sr) * | 2005-02-07 | 2010-12-31 | F. Hoffmann-La Roche Ag. | Heterociklični supstituisani fenil metanoni kao inhibitori glicin transportera 1 |
-
2015
- 2015-04-27 SG SG11201608397UA patent/SG11201608397UA/en unknown
- 2015-04-27 CN CN201580016721.4A patent/CN106163520B/zh active Active
- 2015-04-27 RS RS20180897A patent/RS57535B1/sr unknown
- 2015-04-27 SI SI201530334T patent/SI3137073T1/sl unknown
- 2015-04-27 SG SG10201909382U patent/SG10201909382UA/en unknown
- 2015-04-27 TR TR2018/09598T patent/TR201809598T4/tr unknown
- 2015-04-27 MA MA39927A patent/MA39927B1/fr unknown
- 2015-04-27 ES ES15717916.9T patent/ES2683184T3/es active Active
- 2015-04-27 EP EP15717916.9A patent/EP3137073B1/en active Active
- 2015-04-27 JP JP2017505724A patent/JP6283766B2/ja active Active
- 2015-04-27 MY MYPI2016001545A patent/MY189930A/en unknown
- 2015-04-27 KR KR1020167030222A patent/KR101869185B1/ko active IP Right Grant
- 2015-04-27 PT PT157179169T patent/PT3137073T/pt unknown
- 2015-04-27 WO PCT/EP2015/059037 patent/WO2015165842A1/en active Application Filing
- 2015-04-28 AR ARP150101268A patent/AR100209A1/es not_active Application Discontinuation
-
2016
- 2016-09-13 PH PH12016501784A patent/PH12016501784A1/en unknown
- 2016-10-26 US US15/334,722 patent/US9877963B2/en active Active
-
2018
- 2018-07-25 HR HRP20181205TT patent/HRP20181205T1/hr unknown
- 2018-08-06 CY CY20181100809T patent/CY1120508T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
KR101869185B1 (ko) | 2018-06-19 |
CN106163520A (zh) | 2016-11-23 |
US20170042888A1 (en) | 2017-02-16 |
MA39927B1 (fr) | 2018-09-28 |
MA39927A (fr) | 2017-03-08 |
MY189930A (en) | 2022-03-22 |
EP3137073A1 (en) | 2017-03-08 |
EP3137073B1 (en) | 2018-06-06 |
AR100209A1 (es) | 2016-09-21 |
ES2683184T3 (es) | 2018-09-25 |
KR20160130517A (ko) | 2016-11-11 |
CN106163520B (zh) | 2019-12-13 |
CY1120508T1 (el) | 2019-07-10 |
PH12016501784B1 (en) | 2016-11-07 |
RS57535B1 (sr) | 2018-10-31 |
JP6283766B2 (ja) | 2018-02-21 |
SI3137073T1 (sl) | 2018-09-28 |
WO2015165842A1 (en) | 2015-11-05 |
TR201809598T4 (tr) | 2018-07-23 |
SG10201909382UA (en) | 2019-11-28 |
PT3137073T (pt) | 2018-07-27 |
JP2017511385A (ja) | 2017-04-20 |
HRP20181205T1 (hr) | 2018-09-21 |
US9877963B2 (en) | 2018-01-30 |
PH12016501784A1 (en) | 2016-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL247841A0 (en) | Heterocyclic compounds for use in the treatment of disorders mediated by pi3k gamma | |
HK1243325A1 (zh) | 用於治療視覺障礙的組合物和方法 | |
ZA201707303B (en) | Compositions and methods for the treatment of immunodeficiency | |
PT3811943T (pt) | Composto para uso no tratamento de distúrbios oculares | |
HRP20181205T1 (hr) | Glyt1 inhibitori za uporabu u liječenju hematoloških poremećaja | |
IL247589A0 (en) | Dihydropyridine mgat2 inhibitors for use in the treatment of metabolic disorders | |
IL247699A0 (en) | Preparations and methods for the treatment of kidney disorders | |
IL251904B (en) | Epilimod for use in the treatment of melanoma | |
PL3122349T3 (pl) | Kompozycje do leczenia samotrawienia | |
IL263804A (en) | Wnt inhibitors for use in the treatment of fibrosis | |
HK1220374A1 (zh) | 用於治療碳氧血紅蛋白血症的組合物和方法 | |
PT3160464T (pt) | 6-hidroxibuspirona para uso no tratamento de transtornos do movimento | |
SI3093022T1 (sl) | GATA-3 inhibitorji za uporabo pri zdravljenju astme, ki jo povzroča TH2 | |
IL251345B (en) | Preparations for use in the treatment of peri-implantitis | |
IL246855A0 (en) | Materials for use in the treatment of retinitis | |
HK1225994A1 (zh) | 用於治療過敏性病症的組合物 | |
IL251840A0 (en) | Use of femiroplast in the treatment of severe asthma | |
IL248494A0 (en) | Methods and compositions for the treatment of fat storage diseases | |
EP3200795A4 (en) | Use of agents for treating fat-related disorders | |
ZA201408464B (en) | Composition for the use in treatment of asthma |